BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Inhibition of LSD1 phosphorylation alleviates colitis symptoms induced by dextran sulfate sodium

  • Oh, Chaeyoon (Department of Biological Sciences, Cellular Heterogeneity Research Center, Sookmyung Women's University) ;
  • Jeong, Jiyeong (Research Institute of Women's Health, Sookmyung Women's University) ;
  • Oh, Se Kyu (Department of Biological Sciences, Creative Research Initiative Center for Chromatin Dynamics, Seoul National University) ;
  • Baek, Sung Hee (Department of Biological Sciences, Creative Research Initiative Center for Chromatin Dynamics, Seoul National University) ;
  • Kim, Keun Il (Department of Biological Sciences, Cellular Heterogeneity Research Center, Sookmyung Women's University)
  • Received : 2019.11.29
  • Accepted : 2020.01.16
  • Published : 2020.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Inflammatory Bowel Disease is caused by an acute or chronic dysfunction of the mucosal inflammatory system in the intestinal tract. In line with the results of our previous study, wherein we found that the PKCα-LSD1-NF-κB signaling plays a critical role in the prolonged activation of the inflammatory response, we aimed to investigate the effect of signaling on colitis in the present study. Lsd1 S112A knock-in (Lsd1SA/SA) mice, harboring a deficiency in phosphorylation by PKCα, exhibited less severe colitis symptoms and a relatively intact colonic epithelial lining in dextran sulfate sodium (DSS)-induced colitis models. Additionally, a reduction in pro-inflammatory gene expression and immune cell recruitment into damaged colon tissues in Lsd1SA/SA mice was observed upon DSS administration. Furthermore, LSD1 inhibition alleviated colitis symptoms and reduced colonic inflammatory responses. Both LSD1 phosphorylation and its activity jointly play a role in the progression of DSS-induced colitis. Therefore, the inhibition of LSD1 activity could potentially protect against the colonic inflammatory response.

Keywords

References

  1. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347, 417-429 https://doi.org/10.1056/NEJMra020831
  2. Kostic M, Djakovic L, Sujic R, Godman B and Jankovic SM (2016) Inflammatory bowel diseases (crohn's disease and ulcerative colitis): cost of treatment in serbia and the implications. Appl Health Econ Health Policy 15, 85-93 https://doi.org/10.1007/s40258-016-0272-z
  3. Kang I, Lee BC, Lee JY et al (2019) Interferon-${\gamma}$-mediated secretion of tryptophanyl-tRNA synthetases has a role in protection of human umbilical cord blood-derived mesenchymal stem cells against experimental colitis. BMB Rep 52, 318-323 https://doi.org/10.5483/bmbrep.2019.52.5.134
  4. Yu YR and Rodriguez JR (2017) Clinical presentation of crohn's, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg 26, 349-355 https://doi.org/10.1053/j.sempedsurg.2017.10.003
  5. Oliva-Hemker M, Carvalho RS, Cuffari C, Abadom V, Dilworth HP and Thompson R (2006) Indeterminate colitis: A significant subgroup of pediatric IBD. Inflamm Bowel Dis 12, 258-262 https://doi.org/10.1097/01.MIB.0000215093.62245.b9
  6. Alex P, Zachos NC, Nguyen T et al (2009) Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-Induced colitis. Inflamm Bowel Dis 15, 341-352 https://doi.org/10.1002/ibd.20753
  7. Strober W, Fuss IJ and Blumberg RS (2002) The immunology of mucosal models of inflammation. Annu Rev Immunol 20, 495-549 https://doi.org/10.1146/annurev.immunol.20.100301.064816
  8. Khor B, Gardet A and Xavier RJ (2011) Genetics and pathogenesis of inflammatory bowel disease. Nature 474, 307-317 https://doi.org/10.1038/nature10209
  9. Chassaing B, Aitken JD, Malleshappa M and Vijay-Kumar M (2014) Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol 104, 15.25.11-15.25.14
  10. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y and Nakaya R (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98, 694-702 https://doi.org/10.1016/0016-5085(90)90290-h
  11. Wirtz S, Neufert C, Weigmann B and Neurath MF (2007) Chemically induced mouse models of intestinal inflammation. Nat Protoc 2, 541-546 https://doi.org/10.1038/nprot.2007.41
  12. Nakamura M, Saito H, Kasanuki J, Tamura Y and Yoshida S (1992) Cytokine production in patients with inflammatory bowel disease. Gut 33, 933-937 https://doi.org/10.1136/gut.33.7.933
  13. Atreya I, Atreya R and Neurath MF (2008) $NF-{\kappa}B$ in inflammatory bowel disease. J Intern Med 263, 591-596 https://doi.org/10.1111/j.1365-2796.2008.01953.x
  14. Schottelius AJ and Dinter H (2006) Cytokines, $NF-{\kappa}B$, microenvironment, intestinal inflammation and cancer. Cancer Treat Res 130, 67-87 https://doi.org/10.1007/0-387-26283-0_3
  15. Viennois E, Chen F and Merlin D (2013) $NF-{\kappa}B$ pathway in colitis-associated cancers. Transl Gastrointest Cancer 2, 21-29
  16. McDaniel DK, Eden K, Ringel VM and Allen IC (2016) Emerging roles for noncanonical $NF-{\kappa}B$ signaling in the modulation of inflammatory bowel disease pathobiology. Inflamm Bowel Dis 22, 2265-2279 https://doi.org/10.1097/MIB.0000000000000858
  17. Neurath MF, Fuss I, Schurmann G et al (1998) Cytokine gene transcription by $NF-{\kappa}B$ family members in patients with inflammatory bowel disease. Ann N Y Acad Sci 859, 149-159 https://doi.org/10.1111/j.1749-6632.1998.tb11119.x
  18. Kim D, Nam HJ, Lee W et al (2018) $PKC{\alpha}$-LSD1-$NF-{\kappa}B$-signaling cascade is crucial for epigenetic control of the inflammatory response. Mol Cell 69, 398-411.e396 https://doi.org/10.1016/j.molcel.2018.01.002
  19. Lu T, Jackson MW, Wang B et al (2009) Regulation of $NF-{\kappa}B$ by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci U S A 107, 46-51
  20. Wei H, Wang B, Miyagi M et al (2013) PRMT5 dimethylates R30 of the p65 subunit to activate $NF-{\kappa}B$. Proc Natl Acad Sci U S A 110, 13516-13521 https://doi.org/10.1073/pnas.1311784110
  21. Culhane JC and Cole PA (2007) LSD1 and the chemistry of histone demethylation. Curr Opin Chem Biol 11, 561-568 https://doi.org/10.1016/j.cbpa.2007.07.014
  22. Shi Y, Lan F, Matson C et al (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941-953 https://doi.org/10.1016/j.cell.2004.12.012
  23. Forneris F, Binda C, Dall'Aglio A, Fraaije MW, Battaglioli E and Mattevi A (2006) A highly specific mechanism of histone H3-K4 recognition by histone demethylase LSD1. J Biol Chem 281, 35289-35295 https://doi.org/10.1074/jbc.M607411200
  24. Culhane JC, Szewczuk LM, Liu X, Da G, Marmorstein R and Cole PA (2006) A mechanism-based inactivator for histone demethylase LSD1. J Am Chem Soc 128, 4536-4537 https://doi.org/10.1021/ja0602748
  25. Huang J, Sengupta R, Espejo AB et al (2007) p53 is regulated by the lysine demethylase LSD1. Nature 449, 105-108 https://doi.org/10.1038/nature06092
  26. Baek SH and Kim KI (2016) Regulation of $HIF-1{\alpha}$ stability by lysine methylation. BMB Rep 49, 245-246 https://doi.org/10.5483/BMBRep.2016.49.5.053
  27. Lee JY, Park JH, Choi HJ et al (2017) LSD1 demethylates $HIF1{\alpha}$ to inhibit hydroxylation and ubiquitin-mediated degradation in tumor angiogenesis. Oncogene 36, 5512-5521 https://doi.org/10.1038/onc.2017.158
  28. Peng B, Wang J, Hu Y et al (2015) Modulation of LSD1 phosphorylation by CK2/WIP1 regulates RNF168-dependent 53BP1 recruitment in response to DNA damage. Nucleic Acids Res 43, 5936-5947 https://doi.org/10.1093/nar/gkv528
  29. Peng B, Shi R, Jiang W et al (2017) Phosphorylation of LSD1 by PLK1 promotes its chromatin release during mitosis. Cell Biosci 7, 15 https://doi.org/10.1186/s13578-017-0142-x
  30. Nam HJ, Boo K, Kim D et al (2014) Phosphorylation of LSD1 by $PKC{\alpha}$ is crucial for circadian rhythmicity and phase resetting. Mol Cell 53, 791-805 https://doi.org/10.1016/j.molcel.2014.01.028
  31. Wirtz S, Popp V, Kindermann M et al (2017) Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc 12, 1295-1309 https://doi.org/10.1038/nprot.2017.044
  32. Feng J, Xu G, Liu J et al (2016) Phosphorylation of LSD1 at Ser112 is crucial for its function in induction of EMT and metastasis in breast cancer. Breast Cancer Res Treat 159, 443-456 https://doi.org/10.1007/s10549-016-3959-9
  33. Boulding T, McCuaig RD, Tan A et al (2018) LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer. Sci Rep 8, 73 https://doi.org/10.1038/s41598-017-17913-x
  34. Farhadi A, Keshavarzian A, Ranjbaran Z, Fields JZ and Banan A (2006) The role of protein kinase C isoforms in modulating injury and repair of the intestinal barrier. J Pharmacol Exp Ther 316, 1-7 https://doi.org/10.1124/jpet.105.085449
  35. Yang GJ, Lei PM, Wong SY, Ma DL and Leung CH (2018) Pharmacological inhibition of LSD1 for cancer treatment. Molecules 23, 3194 https://doi.org/10.3390/molecules23123194
  36. Fu X, Zhang P and Yu B (2017) Advances toward LSD1 inhibitors for cancer therapy. Future Med Chem 9, 1227-1242 https://doi.org/10.4155/fmc-2017-0068